⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2656903 | 0.71 | — | — | |
| SCHEMBL11655643 | 0.71 | — | — | |
| SCHEMBL15017494 | 0.67 | — | — | |
| SCHEMBL17398305 | 0.64 | — | — | |
| SCHEMBL15542974 | 0.62 | — | — | |
| SCHEMBL7532554 | 0.59 | — | — | |
| SCHEMBL15934356 | 0.57 | — | — | |
| SCHEMBL7458563 | 0.57 | — | — | |
| SCHEMBL2467258 | 0.57 | — | — | |
| SCHEMBL5074259 | 0.55 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1824856-B1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-23 | — | — | EP | disclosed |
| US-8394955-B2 | 2,4 (4,6) pyrimidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-03-12 | — | — | US | disclosed |
| US-8148388-B2 | 2,4 (4,6) pyrimidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-04-03 | — | — | US | disclosed |
| US-20120065395-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | FREYNE EDDY JEAN EDGARD (BE) | 2012-03-15 | — | — | US | disclosed |
| US-20100160310-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-24 | — | — | US | disclosed |
| EP-1824856-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006061415-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-15 | — | — | WO | disclosed |